Myeloid Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Myeloid Therapeutics's estimated annual revenue is currently $4.7M per year.
- Myeloid Therapeutics's estimated revenue per employee is $77,500
- Myeloid Therapeutics's total funding is $123M.
Employee Data
- Myeloid Therapeutics has 61 Employees.
- Myeloid Therapeutics grew their employee count by 20% last year.
Myeloid Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Co-Founder | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP Translational Research | Reveal Email/Phone |
4 | VP Discovery Research | Reveal Email/Phone |
5 | VP, Head CMC | Reveal Email/Phone |
6 | VP, Clinical | Reveal Email/Phone |
7 | SVP Finance | Reveal Email/Phone |
8 | Associate Director, CMC Operations | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Snr. Director, Discovery Research | Reveal Email/Phone |
Myeloid Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Myeloid Therapeutics?
Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. We’re passionate about scientific inquiry, collaborating to solve big clinical problems, and most of all, helping patients. Myeloid is powered by our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. And we are working to build a team of talented, driven scientists and other biotech industry experts, who will turn these discoveries into novel, lifesaving treatments for patients. Our ATAKTM platform integrates the accumulated know-how and experience of our founders and our growing research team, to deliver new products that reprogram innate immune cells to eradicate disease. We have built a platform manufacturing process that reduces cell handling to less than one day, and supports the rapid translation of the company’s lead assets to the clinic: MT-101 for peripheral and cutaneous forms of T cell Lymphoma, MT-102 for HER2 expressing solid tumors, MT-103 for TROP2 expressing solid tumors, and MT-201, our primed monocyte that stimulates T cells to fight glioblastoma. We expect to initiate clinical trials for several of these product candidates in the first half of 2021, a mere 18-months from our founding. We invite you to join us on this journey – patients are waiting. – Daniel Getts, CEO
keywords:N/A$123M
Total Funding
61
Number of Employees
$4.7M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Myeloid Therapeutics News
("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late...
The technology can be used alongside Prime Editing to simplify ex vivo and in vivo cell therapy delivery. Myeloid Therapeutics and Prime...
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.9M | 61 | 9% | N/A |
#2 | $8M | 61 | 13% | N/A |
#3 | $7.7M | 61 | 45% | N/A |
#4 | $7.1M | 61 | -3% | N/A |
#5 | $8.4M | 62 | 2% | N/A |